Kailera Therapeutics

Biotechnology
Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a broad portfolio of next-generation therapies for obesity and metabolic disorders. The company's pipeline is built around several differentiated incretin-based programs designed to offer improved efficacy and convenience for patients. Kailera's lead assets include KLR-102, a long-acting GLP-1/GIP/glucagon receptor tri-agonist currently in clinical development, as well as oral small molecule GLP-1 receptor agonists. These programs aim to address the global obesity epidemic by providing potent weight loss solutions and managing comorbid conditions such as type 2 diabetes and cardiovascular disease. Formed with a significant capital commitment and a suite of licensed assets from Jiangsu Hengrui Pharmaceuticals, Kailera is led by a management team with extensive experience in the biotechnology and metabolic sectors. The company is positioned to compete in the rapidly expanding incretin market by leveraging its diverse clinical-stage portfolio and focusing on the next wave of innovation in metabolic health.

$1.4B

Market Cap • 11/20/2026

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

7,9

EPS

—

Market Cap

Market Cap

1,4B

EV

539,5M

EV/Revenue

—

EV/EBITDA

-1,4

EV/EBIT

-1,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-46,8%

Total Yield

-46,8%

Payout

0%

Retained Earnings

-654,5M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

387,1%

Capex/OCF

-0,5%

SBC/OCF

—

% PPE

1%

% Goodwill

0%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

2,4

Debt/Equity

0%

Current Ratio

21,8

Quick Ratio

21,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium